Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells

Gene Therapy

Volumn 8, Issue 6, 2001, Pages 477-486

  Wahlers, A ^a   Schwieger, M ^a   Li, Z ^a   Meier Tackmann, D ^a   Lindemann, C ^b   Eckert, H G ^b   Von Laer, D ^a   Baum, C ^a,c  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b BIONTECH AG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Hematopoiesis; Protein stability; Retroviral vector

Indexed keywords

GENE PRODUCT; GREEN FLUORESCENT PROTEIN; TRANSGENIC PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; BLOOD; BLOOD CELL; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA VECTOR; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSDUCTION; HALF LIFE TIME; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MATURATION; MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN STABILITY; PROTEIN SYNTHESIS; REPORTER GENE; RETROVIRUS; STEM CELL; TRANSGENE; TRANSPLANTATION; VIRUS INFECTION; VIRUS TRANSCRIPTION;

ANIMALS; ANTIGENS, CD34; BONE MARROW CELLS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HALF-LIFE; HEMATOPOIETIC STEM CELLS; HUMANS; LUMINESCENT PROTEINS; MICE; MICE, INBRED C57BL; RETROVIRIDAE; T-LYMPHOCYTES; TIME FACTORS; TRANSCRIPTION, GENETIC;

ANIMALIA; RNA VIRUSES; UNIDENTIFIED RETROVIRUS;

EID: 0035070944     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301426     Document Type: Article

References (40)

1. Use of green fluorescent protein variants to monitor gene transfer and expression in mammalian cells
2. Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells
3. Highly efficient transduction of the green fluorescent protein gene in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice
4. Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector
5. Gene marking and gene therapy directed at primary hematopoietic cells
6. Treatment of genetic defects in hematopoietic cell function by gene transfer
7. Gene transfer and transgene expression in hematopoietic cells
8. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse
9. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells
10. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice
11. Long-term multilineage expression in peripheral blood from a Moloney murine leukemia virus vector after serial transplantation of transduced bone marrow cells
12. Dose-dependent transduction of vesicular stomatitis virus G protein-pseudotyped retrovirus vector into human solid tumour cell lines and murine fibroblasts
13. Generation of destabilized green fluorescent protein as a transcription reporter
14. CD34 splice variant: An attractive marker for selection of gene-modified cells
15. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus
16. Entry of amphotropic and 10A1 pseudotyped murine retroviruses is restricted in hematopoietic stem cell lines
17. Superior transduction of mouse hematopoietic stem cells with 10A1 and VSV-G pseudotyped retrovirus vectors
18. Design of 5′ untranslated sequences in retroviral vectors developed for medical use
19. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells
20. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow
21. Establishing chemoresistance in hematopoietic progenitor cells
22. Genetic strategies to inhibit HIV
23. Progress in the use of gene transfer methods to treat genetic blood diseases
24. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor
25. Efficient retroviral-mediated gene transfer to human cord blood stem cells with in vivo repopulating potential
26. High efficiency gene transfer to human hematopoietic SCID-repopulating cells under serum-free conditions
27. Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice
28. A defined window for efficient gene marking of severe combined immunodeficient-repopulating cells using a gibbon ape leukemia virus-pseudotyped retroviral vector
29. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells
30. Activation conditions determine susceptibility of murine primary T-lymphocytes to retroviral infection
31. Stimulation of mouse bone marrow cells with kit ligand, FLT3 ligand, and thrombopoietin leads to efficient retrovirus-mediated gene transfer to stem cells, whereas interleukin 3 and interleukin 11 reduce transduction long-term repopulating cells
32. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors
33. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors
34. Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells
35. Novel retroviral vectors for efficient expression of the multidrug-resistance (mdr-1) gene in early hemopoietic cells
36. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors
37. Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells
38. The potent enhancer activity of the polycythemic strain of spleen focus-forming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer core exclusive target for PEBP/CBF
39. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus
40. Transcriptional targeting of retroviral vectors to the erythroblastic progeny of transduced hematopoietic stem cells